Vor biopharma to present at jefferies and goldman sachs investor conferences

Cambridge, mass., may 25, 2021 (globe newswire) -- vor biopharma (nasdaq: vor or the company), a cell therapy company pioneering engineered hematopoietic stem cell (ehsc) therapies combined with targeted therapies for the treatment of cancer, today announced that the robert ang, mbbs, mba, vor's president and chief executive officer, and nathan jorgensen, ph.d., vor's chief financial officer, are scheduled to present at the following conferences:
VOR Ratings Summary
VOR Quant Ranking